Brief: Immunovant Q1 Net Income USD -120.613 Million

Immunovant

11/08/2025 12:00

Overview

Immunovant fiscal Q1 net loss widens to $120.6 mln, driven by higher R&D costs

Company initiated registrational trials for IMVT-1402 in GD and SjD

Cash balance provides runway through GD readout expected in 2027

Outlook

Immunovant expects GD remission data at ATA meeting in September 2025

Company anticipates top-line results for IMVT-1402 trials in 2027

Immunovant has cash runway through GD readout expected in 2027

Company plans to report D2T RA trial results in 2026

Result Drivers

R&D EXPENSES - Increase driven by clinical trial activities and contract manufacturing costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$120.61 mln
Q1 Basic EPS
-$0.71
Q1 Operating Expenses
$127.22 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Immunovant Inc is $44.50, about 65.3% above its August 8 closing price of $15.46

Press Release: ID:nGNX3qzJLz

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)